Narcolepsy | Executive Insights | Executive Insights (US)

Publish date: February 2019

Login to access report


The narcolepsy market has been characterized by a lack of available and on-label therapies as well as low diagnosis rates because patients often do not seek treatment; however, the market appears poised for expansion over the next ten years. The few available on-label therapies are considered to have high abuse potential, presenting obstacles for prescription as well as administration. Emerging agents are likely to expand treatment options. Some early-phase drugs offer a novel mode of administration or mechanism of action. Furthermore, at least one therapy in development (pitolisant) is not expected to be listed as a controlled substance, which is likely to reduce physician and patient concerns around prescribing, allowing for higher treatment rates. With a combined early- and late-phase development pipeline extending through at least 2027, DRG forecasts strong growth in the narcolepsy market over the next ten years.


  • What are the key areas of unmet need and opportunity in the narcolepsy market?
  • What is the expected impact of novel therapy launches, especially drugs with novel mechanisms of action?
  •  How does each current and future player influence the market and how will this change in the future? ·
  • What are the key drivers and limiters of the narcolepsy market?


United States Primary Research 3 KOL interviews in November 2018


Jazz Pharmaceuticals, Teva, Harmony Biosciences

Key Drugs Covered

Xyrem, Nuvigil, Provigil, pitolisant, solriamfetol


Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.

Table of contents

  • Executive Insights (US)
    • Narcolepsy-Executive-Insights

Author(s): Meghan Hennis, PhD; Andrea Witt, PhD

Meghan Hennis, PhD is a Senior Analyst in the New Product Development group at Decision Resources Group. She has over 10 years of research experience in the biological sciences followed by 2 years as part of the Consulting team at DRG where she provided key insights to client business questions across a range of therapeutic areas. Dr. Hennis received her in Neuroscience from University of Texas Southwestern Medical Center and her in Biology from University of North Carolina Chapel Hill.

Andrea S. Witt, is Therapy Leader of the Central Nervous System and Ophthalmology Disorders Portfolio at Decision Resources Group where she oversees a team of 14 Business Insights Analysts and Senior Directors responsible for market research encompassing Neurology, Psychiatry, Pain, and Ophthalmology.  Dr. Witt has been with Decision Resources Group for over 12 years, following CNS markets and trends. Her interests beyond specific CNS indications included the market potential for neuroprotectants and the impact of biomarkers on CNS markets. Dr. Witt’s research, analysis, and commentaries have appeared in Barron’s, Pharmaceutical Executive, PharmaVoice, Nature Medicine, and CNBC. Dr. Witt’s previous experience includes 10 years of scientific research conducted on neurodegenerative disorders at Harvard Medical School/Brigham and Women’s Hospital, Duke University, and the University of Texas-Southwestern Medical Center, where she earned her degree.